Статті в журналах з теми "Baloxavir"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Baloxavir".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Sato, Masatoki, Emi Takashita, Masahiko Katayose, Kenji Nemoto, Nobuko Sakai, Koichi Hashimoto, and Mitsuaki Hosoya. "Detection of Variants With Reduced Baloxavir Marboxil Susceptibility After Treatment of Children With Influenza A During the 2018–2019 Influenza Season." Journal of Infectious Diseases 222, no. 1 (February 8, 2020): 121–25. http://dx.doi.org/10.1093/infdis/jiaa061.
Повний текст джерелаAndo, Yoshinori, Takeshi Noshi, Kenji Sato, Toru Ishibashi, Yuki Yoshida, Takahiro Hasegawa, Motoyasu Onishi, et al. "Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection." Journal of Antimicrobial Chemotherapy 76, no. 1 (October 10, 2020): 189–98. http://dx.doi.org/10.1093/jac/dkaa393.
Повний текст джерелаTaieb, Vanessa, Hidetoshi Ikeoka, Fang-Fang Ma, Katarzyna Borkowska, Samuel Aballea, Keiko Tone, and Nobuo Hirotsu. "A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients." Terapevticheskii arkhiv 92, no. 11 (December 26, 2020): 122–31. http://dx.doi.org/10.26442/00403660.2020.11.000870.
Повний текст джерелаBaker, Danial E. "Baloxavir Marboxil." Hospital Pharmacy 54, no. 3 (April 1, 2019): 165–69. http://dx.doi.org/10.1177/0018578719841044.
Повний текст джерелаShah, Sunish, Dayna McManus, Nika Bejou, Samad Tirmizi, Ginger E. Rouse, Steven M. Lemieux, Diana Gritsenko, and Jeffrey E. Topal. "Clinical outcomes of baloxavir versus oseltamivir in patients hospitalized with influenza A." Journal of Antimicrobial Chemotherapy 75, no. 10 (July 26, 2020): 3015–22. http://dx.doi.org/10.1093/jac/dkaa252.
Повний текст джерелаter Horst, Sebastiaan, Yaiza Fernandez-Garcia, Marcella Bassetto, Stephan Günther, Andrea Brancale, Johan Neyts, and Joana Rocha-Pereira. "Enhanced efficacy of endonuclease inhibitor baloxavir acid against orthobunyaviruses when used in combination with ribavirin." Journal of Antimicrobial Chemotherapy 75, no. 11 (August 7, 2020): 3189–93. http://dx.doi.org/10.1093/jac/dkaa337.
Повний текст джерелаYoshino, Yusuke, Keita Misu, Yoshitaka Wakabayashi, Yasuo Ota, and Takatoshi Kitazawa. "2644. Evaluation of Clinical Course and Heath-Related Quality-of-Life Following Treatment with Oseltamivir, Laninamivir, and Baloxavir Marboxil in Adult Patients with Seasonal Influenza: Prospective Observational Study." Open Forum Infectious Diseases 6, Supplement_2 (October 2019): S925. http://dx.doi.org/10.1093/ofid/ofz360.2322.
Повний текст джерелаKiso, Maki, Seiya Yamayoshi, Yuri Furusawa, Masaki Imai, and Yoshihiro Kawaoka. "Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil." Viruses 11, no. 11 (November 15, 2019): 1066. http://dx.doi.org/10.3390/v11111066.
Повний текст джерелаSelvanayagam, Stephen, Amy Kang, and David Ha. "Baloxavir Marboxil: A New Antiviral for Acute Influenza." Journal of Contemporary Pharmacy Practice 66, no. 4 (January 1, 2020): 33–38. http://dx.doi.org/10.37901/jcphp19-00004.
Повний текст джерелаSeldeslachts, Laura, Cato Jacobs, Birger Tielemans, Eliane Vanhoffelen, Lauren Van der Sloten, Stephanie Humblet-Baron, Lieve Naesens, et al. "Overcome Double Trouble: Baloxavir Marboxil Suppresses Influenza Thereby Mitigating Secondary Invasive Pulmonary Aspergillosis." Journal of Fungi 8, no. 1 (December 21, 2021): 1. http://dx.doi.org/10.3390/jof8010001.
Повний текст джерелаShah, Sunish, Dayna McManus, Nika Bejou, Samad Tirmizi, Ginger Rouse, Steven Lemieux, Diana Gritsenko, and Jeffrey E. Topal. "2645. Clinical Outcomes of Oseltamivir vs. Baloxavir in Patients Hospitalized with Influenza A." Open Forum Infectious Diseases 6, Supplement_2 (October 2019): S925. http://dx.doi.org/10.1093/ofid/ofz360.2323.
Повний текст джерелаNeuberger, Eddie, Chris Wallick, Devika Chawla, and Rita de Cassia Castro. "1518. Real-World Comparative Effectiveness of Baloxavir Marboxil versus Oseltamivir on Influenza-Related Complication and Resource Utilization." Open Forum Infectious Diseases 7, Supplement_1 (October 1, 2020): S761—S762. http://dx.doi.org/10.1093/ofid/ofaa439.1699.
Повний текст джерелаAsher, Jason, Annabelle Lemenuel-Diot, Matthew Clay, David P. Durham, Luis Mier-y-Teran-Romero, Carlos J. Arguello, Sebastien Jolivet, et al. "Novel modelling approaches to predict the role of antivirals in reducing influenza transmission." PLOS Computational Biology 19, no. 1 (January 6, 2023): e1010797. http://dx.doi.org/10.1371/journal.pcbi.1010797.
Повний текст джерелаKoshimichi, Hiroki, Sylvie Retout, Valérie F. Cosson, Stefan De Buck, Yoshiyuki Tsuda, Toru Ishibashi, and Toshihiro Wajima. "1536. Population Pharmacokinetic Analysis of Baloxavir Morboxil, a Cap-Dependent Endonuclease Inhibitor, in Adult and Adolescent Healthy Subjects and Influenza Patients and Exposure-Response Relationships in the Patients at High-Risk of Influenza Complications." Open Forum Infectious Diseases 6, Supplement_2 (October 2019): S559—S560. http://dx.doi.org/10.1093/ofid/ofz360.1400.
Повний текст джерелаHeo, Young-A. "Baloxavir: First Global Approval." Drugs 78, no. 6 (April 2018): 693–97. http://dx.doi.org/10.1007/s40265-018-0899-1.
Повний текст джерелаKiso, Maki, Seiya Yamayoshi, Jurika Murakami, and Yoshihiro Kawaoka. "Baloxavir Marboxil Treatment of Nude Mice Infected With Influenza A Virus." Journal of Infectious Diseases 221, no. 10 (December 14, 2019): 1699–702. http://dx.doi.org/10.1093/infdis/jiz665.
Повний текст джерелаAbraham, George M., Jacob B. Morton, and Louis D. Saravolatz. "Baloxavir: A Novel Antiviral Agent in the Treatment of Influenza." Clinical Infectious Diseases 71, no. 7 (February 5, 2020): 1790–94. http://dx.doi.org/10.1093/cid/ciaa107.
Повний текст джерелаInce, William L., Fraser B. Smith, Julian J. O’Rear, and Michael Thomson. "Treatment-Emergent Influenza Virus Polymerase Acidic Substitutions Independent of Those at I38 Associated With Reduced Baloxavir Susceptibility and Virus Rebound in Trials of Baloxavir Marboxil." Journal of Infectious Diseases 222, no. 6 (April 7, 2020): 957–61. http://dx.doi.org/10.1093/infdis/jiaa164.
Повний текст джерелаNtem-Mensah, Afua Duker, Emily Heil, Mehrnaz Pajoumand, Ronald Rabinowitz, Samuel Galvagno, and Gregory Schrank. "2256. Baloxavir Marboxil in Combination with Oseltamivir in Two Critically Ill Patients with Influenza A (H1N1; 2009 strain) on Veno-Venous Extra-Corporal Membranous Oxygenation." Open Forum Infectious Diseases 6, Supplement_2 (October 2019): S772. http://dx.doi.org/10.1093/ofid/ofz360.1934.
Повний текст джерелаCheckmahomed, Liva, Zeineb M’hamdi, Julie Carbonneau, Marie-Christine Venable, Mariana Baz, Yacine Abed, and Guy Boivin. "Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains." Journal of Infectious Diseases 221, no. 1 (August 16, 2019): 63–70. http://dx.doi.org/10.1093/infdis/jiz418.
Повний текст джерелаLee, Leo Y., Jie Zhou, Paulina Koszalka, Rebecca Frise, Rubaiyea Farrukee, Keiko Baba, Shahjahan Miah, et al. "Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model." PLOS Pathogens 17, no. 5 (May 6, 2021): e1009527. http://dx.doi.org/10.1371/journal.ppat.1009527.
Повний текст джерелаSlomski, Anita. "Baloxavir Protects Against Household Influenza Spread." JAMA 324, no. 12 (September 22, 2020): 1129. http://dx.doi.org/10.1001/jama.2020.17522.
Повний текст джерелаMahendro, Della Sulamita. "Penggunaan Antivirus untuk COVID-19." Cermin Dunia Kedokteran 48, no. 7 (July 1, 2021): 419. http://dx.doi.org/10.55175/cdk.v48i7.1459.
Повний текст джерелаDufrasne, François. "Baloxavir Marboxil: An Original New Drug against Influenza." Pharmaceuticals 15, no. 1 (December 24, 2021): 28. http://dx.doi.org/10.3390/ph15010028.
Повний текст джерелаHirotsu, Nobuo, Hiroki Sakaguchi, Chisako Sato, Toru Ishibashi, Keiko Baba, Shinya Omoto, Takao Shishido, et al. "Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes." Clinical Infectious Diseases 71, no. 4 (September 20, 2019): 971–81. http://dx.doi.org/10.1093/cid/ciz908.
Повний текст джерелаŚwierczyńska, Magdalena, Dagmara M. Mirowska-Guzel, and Edyta Pindelska. "Antiviral Drugs in Influenza." International Journal of Environmental Research and Public Health 19, no. 5 (March 4, 2022): 3018. http://dx.doi.org/10.3390/ijerph19053018.
Повний текст джерелаMazuchowski, Michał, and Łukasz Puchała. "Baloxavir marboxil as a therapeutic option to treat influenza in Poland." Farmacja Polska 76, no. 8 (September 28, 2020): 438–41. http://dx.doi.org/10.32383/farmpol/127828.
Повний текст джерелаUyeki, Timothy M. "Baloxavir for Postexposure Prophylaxis against Influenza in Households." New England Journal of Medicine 383, no. 4 (July 23, 2020): 389–90. http://dx.doi.org/10.1056/nejme2022702.
Повний текст джерелаMushtaq, Ammara. "Baloxavir: game-changer or much ado about nothing?" Lancet Respiratory Medicine 6, no. 12 (December 2018): 903–4. http://dx.doi.org/10.1016/s2213-2600(18)30469-7.
Повний текст джерелаFujita, Jiro. "Introducing the new anti-influenza drug, baloxavir marboxil." Respiratory Investigation 58, no. 1 (January 2020): 1–3. http://dx.doi.org/10.1016/j.resinv.2019.10.005.
Повний текст джерелаShirley, Matt. "Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza." Drugs 80, no. 11 (June 29, 2020): 1109–18. http://dx.doi.org/10.1007/s40265-020-01350-8.
Повний текст джерелаPortsmouth, Simon, Keiko Kawaguchi, Takeki Uehara, and Frederick G. Hayden. "Comment to: Baloxavir efficacy in North American Adults." European Journal of Internal Medicine 72 (February 2020): 99–101. http://dx.doi.org/10.1016/j.ejim.2019.11.005.
Повний текст джерелаRosenberg, Karen. "Baloxavir Effective in Preventing Influenza in Household Contacts." AJN, American Journal of Nursing 120, no. 11 (November 2020): 1. http://dx.doi.org/10.1097/01.naj.0000721956.76718.33.
Повний текст джерелаWang, Yiyun, Xiaofang Lv, Zihui Meng, Zhibin Xu, Zhonghui Zheng, Jiarong Li, and Min Xue. "Fast and Efficient Synthesis of Racemic Baloxavir Catalyzed by Strong Solid Acid under Microwave Conditions." Crystals 12, no. 7 (June 23, 2022): 891. http://dx.doi.org/10.3390/cryst12070891.
Повний текст джерелаSaim-Mamoun, Amel, Yacine Abed, Julie Carbonneau, and Guy Boivin. "Generation and Characterization of Drug-Resistant Influenza B Viruses Selected In Vitro with Baloxavir Acid." Pathogens 11, no. 9 (September 15, 2022): 1048. http://dx.doi.org/10.3390/pathogens11091048.
Повний текст джерелаBaker, Jeffrey, Stanley L. Block, Balpreet Matharu, Laura Burleigh Macutkiewicz, Steffen Wildum, Sophie Dimonaco, Neil Collinson, Barry Clinch, and Pedro A. Piedra. "Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children." Pediatric Infectious Disease Journal 39, no. 8 (May 19, 2020): 700–705. http://dx.doi.org/10.1097/inf.0000000000002747.
Повний текст джерелаYokoyama, Takato, Hiroki Sakaguchi, Toru Ishibashi, Takao Shishido, Pedro A. Piedra, Chisako Sato, Kenji Tsuchiya, and Takeki Uehara. "Baloxavir Marboxil 2% Granules in Japanese Children With Influenza." Pediatric Infectious Disease Journal 39, no. 8 (March 12, 2020): 706–12. http://dx.doi.org/10.1097/inf.0000000000002748.
Повний текст джерелаHayden, Frederick G., Norio Sugaya, Nobuo Hirotsu, Nelson Lee, Menno D. de Jong, Aeron C. Hurt, Tadashi Ishida, et al. "Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents." New England Journal of Medicine 379, no. 10 (September 6, 2018): 913–23. http://dx.doi.org/10.1056/nejmoa1716197.
Повний текст джерелаIkematsu, Hideyuki, Frederick G. Hayden, Keiko Kawaguchi, Masahiro Kinoshita, Menno D. de Jong, Nelson Lee, Satoru Takashima, Takeshi Noshi, Kenji Tsuchiya, and Takeki Uehara. "Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts." New England Journal of Medicine 383, no. 4 (July 23, 2020): 309–20. http://dx.doi.org/10.1056/nejmoa1915341.
Повний текст джерелаKikuchi, Toshiaki, and Akira Watanabe. "Baloxavir heralds a new era in influenza virus biology." Respiratory Investigation 57, no. 1 (January 2019): 1–2. http://dx.doi.org/10.1016/j.resinv.2018.10.002.
Повний текст джерелаO’Hanlon, Ryan, and Megan L. Shaw. "Baloxavir marboxil: the new influenza drug on the market." Current Opinion in Virology 35 (April 2019): 14–18. http://dx.doi.org/10.1016/j.coviro.2019.01.006.
Повний текст джерелаHussar, Daniel A., and Matthew R. Moyer. "Baloxavir marboxil, Fremanezumab-vfrm, Galcanezumab-gnlm, and Lofexidine hydrochloride." Journal of the American Pharmacists Association 59, no. 1 (January 2019): 141–44. http://dx.doi.org/10.1016/j.japh.2018.12.002.
Повний текст джерелаTaniguchi, Keiichi, Yoshinori Ando, Masanori Kobayashi, Shinsuke Toba, Haruaki Nobori, Takao Sanaki, Takeshi Noshi, et al. "Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection." Viruses 14, no. 1 (January 8, 2022): 111. http://dx.doi.org/10.3390/v14010111.
Повний текст джерелаCheckmahomed, Liva, Blandine Padey, Andrés Pizzorno, Olivier Terrier, Manuel Rosa-Calatrava, Yacine Abed, Mariana Baz, and Guy Boivin. "In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses." Viruses 12, no. 10 (October 8, 2020): 1139. http://dx.doi.org/10.3390/v12101139.
Повний текст джерелаTakashita, Emi, Takashi Abe, Hiroko Morita, Shiho Nagata, Seiichiro Fujisaki, Hideka Miura, Masayuki Shirakura, et al. "Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment." Antiviral Research 180 (August 2020): 104828. http://dx.doi.org/10.1016/j.antiviral.2020.104828.
Повний текст джерелаKoshimichi, Hiroki, Toru Ishibashi, and Toshihiro Wajima. "Population Pharmacokinetics of Baloxavir Marboxil in Japanese Pediatric Influenza Patients." Journal of Pharmaceutical Sciences 108, no. 9 (September 2019): 3112–17. http://dx.doi.org/10.1016/j.xphs.2019.04.010.
Повний текст джерелаFujita, Jiro. "Clinical application of baloxavir marboxil in the treatment of influenza." Respiratory Investigation 58, no. 5 (September 2020): 301–4. http://dx.doi.org/10.1016/j.resinv.2020.06.003.
Повний текст джерелаTwabela, Augustin, Masatoshi Okamatsu, Keita Matsuno, Norikazu Isoda, and Yoshihiro Sakoda. "Evaluation of Baloxavir Marboxil and Peramivir for the Treatment of High Pathogenicity Avian Influenza in Chickens." Viruses 12, no. 12 (December 8, 2020): 1407. http://dx.doi.org/10.3390/v12121407.
Повний текст джерелаTakashita, Emi, Shin Murakami, Yoko Matsuzaki, Seiichiro Fujisaki, Hiroko Morita, Shiho Nagata, Misa Katayama, et al. "Antiviral Susceptibilities of Distinct Lineages of Influenza C and D Viruses." Viruses 15, no. 1 (January 15, 2023): 244. http://dx.doi.org/10.3390/v15010244.
Повний текст джерелаOdnovorov, A. I., T. V. Grebennikova, and T. V. Pleteneva. "Specific Influenza Therapy: Current State and Prospects (Review)." Drug development & registration 9, no. 1 (February 26, 2020): 83–91. http://dx.doi.org/10.33380/2305-2066-2020-9-1-83-91.
Повний текст джерела